Lupin gets USFDA approval to market generic skin treatment medication

Lupin on Wednesday stated its American subsidiary has obtained an approval from the US well being regulator to market a generic product used for therapy of pores and skin points.

New Jersey-based Novel Laboratories Inc has obtained the approval from the US Meals and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, Lupin stated in a press release.

The product is the generic model of Hill Dermaceuticals Inc’s Derma-Smoothe/FS Topical Oil.

Lupin stated the product will likely be manufactured at its Somerset facility within the US.

As per the IQVIA MAT March 2023 information, Fluocinolone Acetonide Topical Oil had estimated annual gross sales of USD 9 million within the US.

Lupin shares had been buying and selling 0.67 per cent down at Rs 981.65 apiece on the BSE.

(Solely the headline and film of this report could have been reworked by the Enterprise Normal workers; the remainder of the content material is auto-generated from a syndicated feed.)

First Revealed: Aug 02 2023 | 2:48 PM IST

Source Link

Spread the love

Leave a Reply